
## HALO: | Fused-Core® Particle Technology

Application Note: 178-PR

## High Temperature/ Low pH Stability of HALO 1000 Å ES-C18, 2.7 μm



## **PEAK IDENTITY:**

**STRUCTURES:** 

1. Trastuzumab

## **TEST CONDITIONS:**

Column: HALO 1000 Å ES-C18, 2.7 μm, 2.1 x 50mm

Part Number: 92712-402 Mobile Phase A: Water/ 0.1% TFA Mobile Phase B: Acetonitrile/ 0.1% TFA

Gradient: <u>Time</u> <u>%B</u>

0.0 324.0 38

Flow Rate: 0.4 mL/min Initial Pressure: 81 bar Temperature: 80 °C

Detection: UV 280 nm, PDA Injection Volume: 1.2 μL Sample Solvent: Water

Data Rate: 40 Hz


Response Time: 0.025 sec

Flow Cell: 1 μL

LC System: Shimadzu Nexera X2



1000 Å 2.7µm particle



ES-C18 bonded phase

Trastuzumab (MW ~148 kDa) is a monoclonal antibody used to treat breast cancer. A stability experiment using a HALO 1000 Å ES-C18 column shows excellent reproducibility for 500 injections of trastuzumab. The sterically protected C18 bonded phase enables rugged stability at the elevated temperature and low pH conditions that are typically used for protein analysis.

